Major pharmaceutical manufacturer Pfizer is aiming for the weight loss drug market as blockbuster drugs Wegovy and Ozempic continue surging in demand.
Pfizer is reportedly testing an obesity pill called danuglipron, which would rival competitors’ injection-only drugs.
Investors are reportedly waiting on data from Pfizer’s phase two trials, which is set to be released by year’s end.
According to Pfizer, the company estimates the weight loss drug market could eventually be worth $90 billion.
